Advantest Corp (ATE)

12.61
0.53 4.37
OTC : Technology
Prev Close 12.08
Open 12.60
Day Low/High 12.59 / 12.62
52 Wk Low/High 7.01 / 12.08
Volume 4.21K
Avg Volume 20.40K
Exchange OTC
Shares Outstanding 174.57M
Market Cap 1.71B
EPS 0.62
P/E Ratio N/A
Div & Yield 0.16 (1.70%)

Latest News

Antibe Therapeutics To Present At Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics To Present At Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co.

Antibe Therapeutics Announces CEO Letter To Shareholders

Antibe Therapeutics Announces CEO Letter To Shareholders

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF): To our stakeholders, The recent success of our lead drug, ATB-346, in its Phase 2B gastrointestinal ("GI") safety clinical study was a significant milestone for Antibe and represented a major...

Antibe Therapeutics Provides Financial Update

Antibe Therapeutics Provides Financial Update

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation that recently announced a successful Phase 2B clinical trial demonstrating...

IIROC Trading Resumption - ATE

IIROC Trading Resumption - ATE

Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study For Lead Pain Drug, ATB-346

Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study For Lead Pain Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal ("GI") safety study.

IIROC Trading Halt - ATE

IIROC Trading Halt - ATE

Antibe Therapeutics Announces No Material Change

Antibe Therapeutics Announces No Material Change

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) wishes to advise that it is not aware of any undisclosed material change in the Company's activities that would account for recent market...

Antibe Therapeutics Reports Q3 2018 Interim Financial And Operating Results

Antibe Therapeutics Reports Q3 2018 Interim Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, February 27 th for the fiscal quarter ended December 31, 2017.

Antibe Therapeutics Provides Update On Phase 2B Gastrointestinal Safety Study Of Lead Pain Drug, ATB-346

Antibe Therapeutics Provides Update On Phase 2B Gastrointestinal Safety Study Of Lead Pain Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) would like to confirm the previously announced timing for its Phase 2B double-blind clinical trial of ATB-346.

Antibe Therapeutics Announces Enrollment Of Final Subjects In Phase 2B Gastrointestinal Safety Study Of Lead Pain Drug, ATB-346

Antibe Therapeutics Announces Enrollment Of Final Subjects In Phase 2B Gastrointestinal Safety Study Of Lead Pain Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine, is pleased to announce...

Antibe Therapeutics Engages Brand Institute To Advise On Nonproprietary Name For ATB-346

Antibe Therapeutics Engages Brand Institute To Advise On Nonproprietary Name For ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQB:ATBPF) is pleased to announce that it has engaged Brand Institute, Inc.

Antibe Therapeutics Reports Q2 2018 Interim Financial And Operating Results And Provides Corporate Update

Antibe Therapeutics Reports Q2 2018 Interim Financial And Operating Results And Provides Corporate Update

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, November 28 th for the fiscal quarter ended September 30, 2017.

Antibe Therapeutics Announces Key US Distribution Partnership For Its Subsidiary, Citagenix

Antibe Therapeutics Announces Key US Distribution Partnership For Its Subsidiary, Citagenix

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its subsidiary, Citagenix Inc.

Antibe Therapeutics To Attend 2017 CPhI Worldwide Conference To Continue Partnering Discussions

Antibe Therapeutics To Attend 2017 CPhI Worldwide Conference To Continue Partnering Discussions

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) will be attending the 2017 CPhI Worldwide conference next week in Frankfurt, Germany.

Antibe Therapeutics Announces Enrollment Of First Subjects In Phase 2B GI Safety Study For Lead Drug, ATB-346

Antibe Therapeutics Announces Enrollment Of First Subjects In Phase 2B GI Safety Study For Lead Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF), is pleased to announce that the first eight subjects have been enrolled and are on treatment in its key Phase 2B clinical trial, a...

Antibe Therapeutics Reports Q1 2018 Interim Financial And Operating Results

Antibe Therapeutics Reports Q1 2018 Interim Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE) (OTCQX:ATBPF) filed its financial and operating results on Tuesday, August 29 th for the fiscal quarter ended June 30, 2017.

Antibe Therapeutics Inc. Announces Closing Of Public Offering

Antibe Therapeutics Inc. Announces Closing Of Public Offering

Antibe Therapeutics Inc. (" Antibe" or the " Company") (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today the second and final closing of its previously announced marketed public offering of...

Antibe Therapeutics Receives Approval To Initiate Phase 2 Gastrointestinal Endoscopy Clinical Trial

Antibe Therapeutics Receives Approval To Initiate Phase 2 Gastrointestinal Endoscopy Clinical Trial

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that it has received approval from Health Canada to initiate a Phase 2, double-blind, gastrointestinal endoscopy trial.

Antibe Therapeutics Reports 2017 Year-End Financial And Operating Results

Antibe Therapeutics Reports 2017 Year-End Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, July 28 for the fourth quarter and the year ended March 31, 2017.

Antibe Therapeutics Inc. Announces Closing Of Public Offering

Antibe Therapeutics Inc. (" Antibe" or the " Company") (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today the first closing of its previously announced marketed public offering of units (the...

Antibe Therapeutics Inc. Announces Filing Of Final Short Form Prospectus

Antibe Therapeutics Inc. (" Antibe" or the " Company") (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today that it has filed a final short form prospectus (the " Final Prospectus") with...

Antibe Therapeutics Inc. Announces Pricing Of Offering

Antibe Therapeutics Inc. (" Antibe" or the " Company") (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announces that it will file today an amended and restated preliminary short form prospectus (the...

Antibe Therapeutics Inc. Announces Proposed Offering Of Units

Antibe Therapeutics Inc. (" Antibe" or the " Company") (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today that it has filed a preliminary short form prospectus in connection with a proposed...

Antibe Therapeutics Engages Topstone Research And Appoints Dr Francis Chan As Key Advisor For Phase 2 Clinical Trial Of ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF), a diversified biotechnology company is providing an update on the clinical development program for ATB-346, its lead drug candidate targeting...

Antibe Therapeutics Advances Development Of ATB-352 In Wake Of Growing Global Opioid Epidemic

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) is pleased to announce that is has formally commenced Investigational New Drug ("IND") enabling pre-clinical studies for its second pipeline drug,...

Antibe Therapeutics To Present At Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co.

Antibe Therapeutics Provides Update On Clinical Development Program For Its Lead Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQX:ATBPF) is pleased to provide an update on its clinical development program for ATB-346, its lead drug that targets the global need for a safer drug for...

Antibe Therapeutics Announces Grant Of Stock Options

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) announces that it has granted its directors, officers and employees options to purchase a total of 9,496,000 common shares of Antibe pursuant to...